FLAG peptide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: FLAG peptide
• 英文别名: (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]hexanoic acid
• 化学式: C₄₁H₆₀N₁₀O₂₀
• 分子量: 1013.0
• InChiKey: XZWYTXMRWQJBGX-VXBMVYAYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -12.9
• 重原子数：
  71
• 可旋转键数：
  35
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  526
• 氢给体数：
  17
• 氢受体数：
  23

文献信息

• Modified Annexin Proteins and Methods for preventing Thrombosis
  申请人：Alavita Pharmaceuticals, Inc.

  公开号：EP1839670A2

  公开（公告）日：2007-10-03

  A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to, phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.

  经修饰的附蛋白（最好是附蛋白 V）可用于防止血栓形成，而不会增加出血量。附件蛋白与细胞膜外表面的磷脂酰丝氨酸结合，从而阻止血栓形成所需的凝血酶原复合物的结合。不过，它不会影响止血所需的血小板聚集。修饰的附件蛋白分子可以是附件蛋白的同源二聚体、与一个或多个聚乙二醇链偶联的附件蛋白分子或与另一种蛋白质偶联的附件蛋白分子。通过增加附件素的分子量，可使修饰的附件素在血液循环中保持足够的时间，从而提供持续的治疗效果。
• Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11
  申请人：BOLDER BIOTECHNOLOGY, INC.

  公开号：US10329337B2

  公开（公告）日：2019-06-25

  Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

  所公开的是白细胞介素-11（IL-11）的半胱氨酸变体以及在治疗应用中制造和使用这种蛋白质的方法。
• Modified annexin proteins and methods for preventing thrombosis
  申请人：SURROMED, INC.

  公开号：US20030166532A1

  公开（公告）日：2003-09-04

  A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.

  经修饰的附蛋白（最好是附蛋白 V）可用于防止血栓形成，而不会增加出血量。附件蛋白与细胞膜外表面的磷脂酰丝氨酸结合，从而阻止血栓形成所需的凝血酶原复合物的结合。不过，它不会影响止血所需的血小板聚集。修饰的附件蛋白分子可以是附件蛋白的同源二聚体、与一个或多个聚乙二醇链偶联的附件蛋白分子或与另一种蛋白质偶联的附件蛋白分子。通过增加附件素的分子量，可使修饰的附件素在血液循环中保持足够的时间，从而提供持续的治疗效果。
• Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
  申请人：SurroMed, Inc.

  公开号：US20040086515A1

  公开（公告）日：2004-05-06

  Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.

  镰状细胞疾病的治疗使用经过修饰的附件蛋白，以延长其在血液循环中的半衰期。
• Monopegylated growth hormone proteins
  申请人：Cox N. George

  公开号：US20050187160A1

  公开（公告）日：2005-08-25

  The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.

  本发明涉及制造具有游离半胱氨酸的可溶性蛋白质的新方法，其中宿主细胞暴露于半胱氨酸阻断剂中。然后，可以对这些方法制得的可溶性蛋白质进行修饰，以提高其有效性。这种修饰包括连接 PEG 分子以形成聚乙二醇化蛋白质。